Related Experiment Videos
Central and peripheral cardiovascular effects of alpha-methylepinephrine.
The Journal of Pharmacology and Experimental Therapeutics
|November 1, 1983
Summary
Alpha-methylepinephrine (alpha-ME) and alpha-methylnorepinephrine (alpha-MNE), metabolites of alpha-methyldopa, were tested for cardiovascular effects. Central administration of alpha-ME showed greater blood pressure-lowering potency than alpha-MNE or epinephrine, suggesting a role in antihypertensive actions.
Area of Science:
- Pharmacology
- Cardiovascular Physiology
- Neuropharmacology
Background:
- Alpha-methyldopa is an antihypertensive drug.
- Its metabolites, alpha-methylepinephrine (alpha-ME) and alpha-methylnorepinephrine (alpha-MNE), may contribute to its therapeutic effects.
- Understanding the cardiovascular actions of these metabolites is crucial.
Purpose of the Study:
- To compare the peripheral and central cardiovascular effects of alpha-ME and alpha-MNE.
- To evaluate their potency relative to endogenous epinephrine.
- To determine the potential contribution of alpha-ME to the antihypertensive action of alpha-methyldopa.
Main Methods:
- Experiments were conducted on urethane-anesthetized normotensive rats.
- Peripheral cardiovascular effects were assessed via intravenous administration.
- Central cardiovascular effects were evaluated through administration into the cerebral ventricle and nucleus of the solitary tract.
Main Results:
- Intravenous alpha-ME lowered blood pressure, while alpha-MNE and epinephrine raised it.
- Central administration of all three catecholamines reduced blood pressure and heart rate.
- Alpha-ME demonstrated greater central depressor potency compared to alpha-MNE and epinephrine.
Conclusions:
- Alpha-ME exhibits significant central antihypertensive activity.
- Its higher potency suggests a key role in the blood pressure-lowering effects of alpha-methyldopa.
- These findings elucidate the central mechanisms underlying alpha-methyldopa's therapeutic action.